PBMC-Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicity of Universal CD19 Chimeric Antigen Receptor T Cell Immunotherapy
Won Lee(Gachon University), Jiwon Yang(Burke Medical Research Institute), James Keck(Jackson Laboratory), Meredith Jackson, Heather Gustafson(Seattle Children's Hospital), Mariliis Ott(Sana Biotechnology (United States)), Destanie Rose(Jackson Laboratory), Kamila Gwiazda(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Joshua A. Gustafson(Seattle Children's Hospital)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CD19 CAR T cell product and disease attributes predict leukemia remission durability
|Journal of Clinical Investigation|2019|355
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
|The FASEB Journal|2017|352